Summary. The distribution of muscarinic acetylcholine receptor protein (mAChR) in the rat forebrain and upper brainstem was described by using a monoclonal antibody (M35) raised against mAChR purified from bovine forebrain homogenates. A method is investigated for light microscopic (LM) and electronmicroscopic (EM) immunocytochemical visualization of reactivity to mAChR-proteins. Putative cholinoceptive neurons including their dendrites were found immunoreactive in the cortical mantle, hippocampus, basal ganglia, amygdala, thalamus and several midbrain regions. In the neocortex, immunoprecipitate with M35 was mainly present in layer 5 pyramidal cells, some layer 3 pyramidal neurons and layer 2 stellate cells, all including their characteristic dendritic profiles of both basal and apical dendrites. In the hippocampus, a variety of pyramidal, granular and non-pyramidal celltypes were stained in various hippocampal cell layers, in the dentate hilus and in stratum oriens of cornu ammonis. Moreover, positively reacting cells occurred in central and lateral amygdala, all parts of the basal ganglia and ventral pallidum. The thalamus was very richly provided with labeled neurons in several nuclei but notably numerous in the ventrolateral, anteroventral and geniculate nuclei. In cortex and hippocampus also some staining of astrocytes occurred. Electron microscopic study of the intracellular distribution of M35 immunoreactivity in all cases showed dense precipitates in the soma cytoplasm in close association with the golgi apparatus, but conspicuous absence near the endoplasmic reticulure. Immunoprecipitate can be followed within the dendritic tree along the microtubular transport system, up to proximal and distal postsynaptic membrane positions, apposing non labeled presynaptic endings. Muscarinic receptor subtype recognition by M35 will be discussed by comparing M35 distribution with cholinergic innervation patterns, muscarinic receptor ligand binding studies and localization of muscarinic receptor subtype mRNAs.
Introduction
The study of identification of neuronal networks has undergone an impressive development as a result of the introduction of immunohistochemical and immunocytochemical methods. By means of polyclonal and monoclonal anti-* To whom offprint requests should be sent bodies directed against chemical neuroactive compounds, essentially any molecular structure related to neuronal elements can be demonstrated once a specific antibody is available. Applications have included the chemical definition of structural neuronal elements, neuroactive proteins, neurotransmitters, neuropeptides, transmitter-related enzymes and so forth. A more recent application of immunocytochemistry to the study of neural systems relates to the neuronal receptors involved in chemical neurotransmission.
Traditionally, the demonstration of neurotransmitter receptors has been the domain of neuropharmacology. The most widely used approach for detection and characterization of receptor proteins has been competitive and noncompetitive binding studies using either synthetic molecules or the native neurotransmitter as an agonist (Kellar et al. 1985; Kuhar and Yamamura 1976; Rotter etal. 1979; Wamsley et al. 1981) . Although receptor binding autoradiography may remain the method of choice for pharmacological applications, the autoradiographic technique holds several serious limitations for the neuroanatomical study of receptor localization, due to the relatively poor resolution at the light microscopic level. Quantitative measures of binding to receptor can be established for cellular regions or layers but only rarely in association with individual neuronal elements. Detection of tritiated receptor ligands at the electron microscopic level has been reported in some studies, but such methods are technically complex, time consuming and probably not suitable for routine applications. Furthermore, ligands often penetrate poorly in brain tissue sections and subsequent visualization of the actual subcellular binding sites is hampered by the relatively large distances the energy quanta travel in the autoradiographic emulsions (Hamel and Beaudet 1987; Kuhar et al. 1981) .
Structural aspects of receptor proteins can now be studied on cellular and subcellular levels as a result of the development of successful methods for receptor protein purification and the subsequent production of monoclonal antibodies to them. Several studies have been recently reported on immunocytochemical demonstration of nicotinic acetylcholine receptors (Deutch etal. 1987; Jacob etal. 1986; Lentz and Chester 1977; Lindstrom 1986; Nghiem et al. 1983; Sealock et al. 1984; Swanson et al. 1983) , glycine receptors (Araki et al. 1988; Triller et al. 1985 ; Van den Pol and Gorcs 1988) , fl-adrenergic receptors (Aoki et al. 1987) , GABA/benzodiazepine receptors (Houser et al. 1988 ; Richards et al. 1987 ) and dopamine receptors (Goldsmith et al. 1979 ).
As part of our analysis of basal forebrain cholinergic systems we became strongly interested in the subcellular, synaptic localization of acetylcholine receptors and in the distribution of cholinoceptive neurons, tn the present paper we report the light-and electron microscopic distribution of immunoreactivity to muscarinic acetylcholine receptor proteins through the use of a highly specific monoclonal antibody raised against bovine forebrain muscarinic receptor (M35). The focus of the present report is on general appearance of the precipitates at LM level and cholinoceptive cell distribution in forebrain and upper brainstem. Some major ultrastructural observations on intracellular immunoreactivity will be described of which preliminary data have been published elsewhere Matsuyama et al. 1988 ).
Materials and methods
Fixation condition. Fixation of the brain was carried out by transcardial perfusion preceeded by a prerinse with 100 ml saline solution of 37 ~ C at a perfusion speed of 20 ml/min. The choice of fixative depended on whether the tissue was used for light microscopic (LM) analysis alone or LM followed by further treatment for electron microscopic (EM) study. For LM purposes optimal results were so far obtained by perfusion with 300 ml (15 ml/min) of the Zamboni fixative (Zamboni and DeMartino 1967) composed of 2% paraformaldehyde and 0.2% picric acid in phosphate buffer (PB) (0.125 M, pH 7.4). In case of subsequent EM analysis, 0.05% glutaraldehyde was added to this solution.
Immediately after the fixation perfusion the fixative was rinsed out by a perfusion with 150 ml of 10% sucrose in 0.1 M PB. Prolonged fixation progressively decreases specific immunostaining and should be avoided. Immunostaining was carried out on either frozen or vibratome sections. In case of frozen sectioning the brains were cryoprotected by overnight storage at 4~ in 30% sucrose in 0.1 M PB. For optimal results, vibratome or frozen sections were cut at a thickness of 20 gm.
Immunocytochemical procedure. In order to obtain a high density of immunocytochemical staining against an unstained light background level, it is critical to suppress nonspecific antibody binding. This was done by repeated and thorough rinsing in phosphate buffered saline (PBS) and pretreatment with normal rabbit serum (NRS) and carrageenan.
Prior to the first antibody incubation, sections were rinsed in PBS, immersed in 0.01% H~Oz in PBS, rinsed again, and incubated in 10% NRS and 0.25% carrageenan (Sigma, type IV) in PBS for 1 h at room temperature. Thereafter, the sections were incubated with the first antibody (M35) diluted 1:2000 in 1% NRS in PBS for 3 days at 4 ~ C under gentle movement of the incubation medium. After incubation the sections were thoroughly rinsed and exposed to 0.25% carrageenan in PBS for 1 h, followed by second antibody incubation with biotinylated rabbit anti-mouse IgM (Zymed) 1:500 in PBS containing 1% NRS overnight at 4~ Sections were again rinsed and immersed in 0.25% carrageenan in PBS (1 h) before the third incubation step in HRP conjugated streptavidin (Zymed) 1:200 in PBS overnight at 4 ~ C. Finally the tissue sections were processed by a diaminobenzidine(DAB)-H2Oz reaction (30 mg DAB and 0.01% H202/100 ml Tris buffer) for at least 4 min, guided by a visual check, and then mounted for LM inspection. Vibratome sections for EM study were postfixed with subsequent exposure to 1% OsO4 for one hour, dehydrated in an ascending series of ethanol, stained en block with 1% uranyl acetate in 70% ethanol and flat-embedded in epon. Selected tissue blocks were cut to ultrathin sections and investigated in Philips 201 or 300 electron microscopes.
Characterization of monoclonal antibody M35. Purification of muscarinic receptor (mAChR) proteins and antibody production have been extensively described elsewhere (Andr6 et al. 1983 (Andr6 et al. , 1987 . The monoclonaI antibody M35 was generated against muscarinic receptor proteins purified from bovine forebrain homogenates. In short the membrane fractions were soIubilized in a 1% digitonin solution in PBS and the solubilized protein solution reacted with a dexetimide coupled affinity gel. The muscarinic receptor proteins bound to the dexetimide were removed from the gel by specific elution with the mAChR antagonists atropine or propylbenzilylcholine mustard. The mAChR protein from the eluate was characterized as a 70 kDa glycoprotein (Andr6 et al. 1983) . Antibody production started by immunizing BALB/c mice with the afffinity-purified mAChR proteins, whereafter the spleen cells were fused with a myeloma cell line. Selected clones were further propagated in ascites in mice and the monoclonals tested for reactivity to radiolabeled purified mAChRs, digitonin solubilized mAChR and Western blots of solubilized membrane preparations. Monoclonal antibody M35 was demonstrated to strongly recognize solubilized muscarinic receptor proteins by indirect immunoprecipitation, and by direct immunoadsorption of mAChR to M35 coupled to Sepharose 4 B (Andr6 et al. , 1987 . Monoclonal antibody M35 was retained after extensive testing procedures that showed it to yield an agonist-like activity in physiologic conditions. M35 mimicked agonist stimulation of the myometrium in guinea pig and rat by causing uterine contractions that were suppressed by atropine, demonstrating immunoprecipitation of M35 to epitopes on mAChRs in rat smooth muscle tissue. That the M35 effects are mediated by the mAChR is further indicated by an M35-induced increase in cyclic GMP levels, comparable to that observed after carbachol stimulation (Leiber et al. 1984) . Recently, immunocytochemical demonstration of M35 binding to mAChR on human fibroblasts culture was shown to be regulated by treatment of the culture ceils with the muscarinic agonist carbamylcholine (Raposo et al. 1987) . Although there is ample evidence that M35 specifically recognizes mAChR proteins (Andr6 et al. , 1987 Leiber et al. 1984; Raposo et al. 1987) , specificity of the M35 immunoprecipitate in rat brain sections were only obtained in an indirect way. We were not able to perform preadsorption of the antibody because of the extremely small quantity of receptor protein yielded by the purification methods. Nevertheless, control experiments were done, e.g. omission of the primary antibody and its substitution by normal mouse serum, or substitution of M35 by different non-matching antibodies of the IgM-or IgGclass. All failed to show immunoreactivity. Application of M35 to rat cerebral cortex tissue was previously reported in preliminary form Matsuyama et al. 1988) .
Results
Immunocytochemical application of monoclonai antibody M35 under the conditions of fixation and after processing as described above yielded a pattern of cellular staining of cell bodies including their dendrites in various parts of the brain. This immunocytochemical staining pattern, although clear against low background activity, showed variations in staining intensity in different parts of the brain and varied from light staining to very dense precipitates.
Staining generally resulted in rather consistent patterns of immunoreactivity, but local variability indicated a high level of susceptibility of the antigen to processes of fixation, perfusion, freezing and thawing, sectioning and immunocytochemical procedure steps. Again, some parts of the brain (e.g. the thalamus, limbic cortex) appeared to be more sensitive to procedural variations than others (e.g. neocortex). As will be argued below, such variations may reflect the generally sensitive character of receptor proteins in immunocytochemistry. in the cortex showed a clear laminar distribution. In most of the cortical mantle, especially in the neocortical areas, predominantly layer 5 cells revealed strong immunoreactivity. Precipitate was found present in the soma cytoplasm extending into the basal and apical dendrites to be followed up to the branching region in layer 1/2. The labeled layer 5 cells were non-spinous at least in their LM appearance (Figs. 1 A, C and 2). In addition, less numerous immunoreactive neurons of various types were detected in layers 2 and 3, and in layer 6. Layer 4 of the neocortex was strikingly devoid of precipitate except for the apical dendrites of the layer 5 pyramidal cells traversing layer 4. In the limbic cortex the pattern was less regular and fewer cells of various types were labeled ( Fig. 1 B) , in all layers except layer 1. In most layers of the cortex but notably in layers 1-3, as well as in the hippocarnpus some staining of astrocytes could be observed (Fig. 1 D) . Such staining was found to j . ,. be increased in aging animals and after brain injury as shall be dealt with in a separate report. Very regular laminar distribution of immunoreactive cells was found in the olfactory bulb where the large mitral cells including their dendrites were densely stained. Immunostaining in the hippocampal formation was characterized by a pattern of labeled pyramidal cells in cornu ammonis fields CA2-CA4, and granular cells in the fascia dentata (FD) (Figs, 3B and 4C) , besides a scattered group of labeled interneurons in stratum oriens and lacunosum-moleculare of CAI-CA3 (Figs. 3A and 4A, B) . Also in the hilar region of the FD a considerable number of cells were immunostained with M35 (Fig. 4C) . Pyramidal cell labeling in the cornu ammonis tend to be more predominant in CA2-3 than in CA1. Strongly labeled cells occurred in the central amygdala, even exceeding the labeling in the basolateral amygdala, whereas medial amygdala staining was moderate.
From the basal ganglia, immunoprecipitate in the striaturn showed a differentiated pattern. Darkly stained neurons were observed mainly in the ventrolateral regions ( Fig. 1 E) . The majority of the striatal cells, however, displayed moderate to light immunoreactivity to M35. Densely staining cells were more numerous in the globus pallidus and related ventral pallidal regions and substantia innominata. Immunoreactivity was considerable in lateral septal nuclei and dorsal cell groups of the medial septum, bed nucleus of the stria terminalis and medial preoptic nucleus.
Diencephalon. Several nuclei in the thalamus revealed distinct staining of large numbers of labeled neurons. This staining was notably rich in the anteroventral, ventrolateral, laterodorsal, and ventroposterior nuclei, and zona incerta ( Fig. 3 C and D) . Less numerous but yet considerable labeling was present in the mediodorsal, parafascicular, entopeduncular, lateral posterior, posterior, ventromedial and dorsal lateral geniculate nuclei. Staining was weak or absent in the central medial, reticular, paraventricular and most medial thalamic regions. In general, it should be noted that the appearance of labeled cells within the various thalamic nuclei was subject to a consistent intranuclear arrangement with regard to the organization of cholinergic input to the thalamus.
Moderate numbers of specifically labeled neurons were present in the anterior hypothalamic area, the ventromedial hypothalamic nucleus, suprachiasmatic nucleus, and lateral hypothalamic area.
Mesencephalon. Immunoreactivity to M35 at midbrain levels was observed in pars compacta and reticulata of the substantia nigra, the red nucleus and scattered over dorsal and ventral midbrain tegmental regions. Likewise a loose pattern of labeled neurons was present in the superior colliculus and periaqueductal grey. Only a few labeled cells were detected in the dorsal raph6 nucleus and interpeduncular nucleus.
Electron microscopic observations
For a more complete understanding of the character of the labeling observed under LM conditions, an ultrastrucrural analysis of subcellular distribution of immunoprecipitate with M35 was carried out for some of the cell groups described above. In the scope of the present paper we will F r o m L M observations, it already became clear that the intracellular precipitate was not uniformly distributed over the cytoplasm (Fig. 1 A and C) . In most cases the pattern of immunoreactivity in the cell soma could be characterized by an irregular patch-like arrangement over the cytoplasm, whereas the nucleus remained unstained. EM observations revealed that this irregular cytoplasmic staining is not the result of an incomplete penetration of antibodies, but probably represents a highly specific staining of muscarinic receptor proteins at a specific stage of synthesis or membrane incorporation. It was a striking observation that binding of M35 did not occur in the neuron's endoplasmic reticulum, suggesting that the antigenic determinants are not expressed in the early phase of formation of polypeptide chains. Patches of immunoreactivity in most cases observed can be associated with the cell's Golgi apparatus and were present on the exterior side in the membrane pouches or vesicles (Fig. 5 A and B) . This specific pattern of immunoreactivity possibly indicates binding of M35 either to epitopes on the receptor protein becoming recognizable in the final stages of protein synthesis. Another explanation may be that in the Golgi apparatus the proteins are incorporated in membrane fragments, where the receptor proteins are molded into their receptor-specific configuration (Lind- Fig. 4A -C. Photomicrographs of M35 immunoprecipitate in the hippocampus CA1 (A), CA2 (B) and fascia dentata (FD) (C) of the dorsal hippocampus. Labeled neurons were observed in stratum oriens, pyramidal cell layers and hilus-granular layer of FD. Probably non-pyramidal cells were positively reacting in or adjacent to the pyramidal cell layers in CA/ and in the transition zone of stratum radiatum and lacunosum-moleculare of CAl. High numbers of immunoreactive pyramidal cells are present in CA~4. Cresyl violet counterstained. Scale bar in A-C = 50 gm strom 1986). Further EM analysis is being currently performed to reveal this matter. In the soma membrane of pyramidal neurons, immunoprecipitate was occasionally observed in a postsynaptic position apposing presynaptic terminal boutons indicating axo-somatic synaptic contacts. F r o m the cell body, the immunoreactivity could be followed into the basal and apical dendrites, sometimes in close proximity to a Golgi complex extending into the dendrite. Immunoreactivity to M35 through the entire apical and basal dendritic tree could be observed in association with the cytoskeleton. The immunoprecipitate possibly represents labeled receptor protein aggregates or proteins incorporated in small vesicular structures being transported from the site of synthesis in the cell-body to the peripheral membrane position where the receptor proteins exert their biological function. It is noteworthy that postsynaptic membrane labeling with M35 was scarce in the proximal main trunk of the apical dendrites where they traverse layer 4. This pattern changes in layers 3 and especially in layers 2 and 1. Here, one could observe considerable branching of dendritic material and at the same time gradually increas- Fig. 5A -G. Pattern of M35 immunoreactivity at the ultrastructural level. A Shows the characteristic distribution of immunoprecipitate in the cytoplasm in this case in a layer 5 pyramidal cell. Immunoprecipitate in all cases studied was always rich in close proximity to the cell's Golgi apparatus (arrow), whereas there is a conspicuous lack of labeling in or near to the endoplasmic reticulum (ER). B Labeling pattern comparable to that in A in a pyramidal cell's apex extending the proximal part of the main shaft of the apical dendrite. Again M35 immunoprecipitate in the immediate vicinity of the Golgi apparatus and lack of staining in the ER. C Typical pattern of tentative transport of immunolabeled mAChR in the major branches of basal and apical dendrites of neocortical pyramidal neurons. D Pattern of cytoplasmic distribution of M35 reactivity in a layer 2 non-pyramidal cell. E-G Examples of distal peripheral dendritic profiles provided with immunoreactivity in the postsynaptic cytoplasm and in high density postsynaptic membrane positions (arrows); compare to the non-labeled postsynaptic membranes indicated by double arrow. Scale bar in A, B and D = 1 gm; in C=0.5 gm and in E--G=200 nm ing numbers of postsynaptic membrane labeling going from proximal to distal dendritic profiles ( Fig. 5C and E-G) . In all cases labeling within the dendritic cytoplasm could be observed in conjunction with labeling at synaptic membrane sites. The pattern of labeling appeared specific for non-spinous pyramidal neurons limited to soma and dendritic cytoplasm and membrane, indicating receptor protein presence in conjunction with a cholinoceptive function.
Discussion

Immunoreactivity of M35, muscarinic ligand binding and cholinergic innervation
The present paper reports on immunocytochemical application in the mammalian brain of a monoclonal antibody to purified muscarinic receptor proteins. Immunoreactivity at the LM level was present in neuronal cell bodies and their dendrites as well as in a number of astrocytes mainly in cortical and hippocampal areas. EM observations on individual labeled neurons support the view that M35 binds to antigenic determinants on muscarinic receptor proteins from early stages of synthesis near the Golgi apparatus in the soma cytoplasm, through stages of transport mediated by the dendritic microtubular system, to positions at the inner surface of the postsynaptic membrane. As such, the labeled neurons stained with M35 appear to represent a population of cholinoceptive neurons employing muscarinic receptors in their synaptic transmission. A comparison of the presently found pattern of immunostained neurons will be made with current data on cholinergic innervation patterns with data from muscarinic receptor-specific ligand autoradiography and with distribution studies of muscarinic receptor mRNAs.
Cortex. In the cortex there is a striking coincidence between the pattern of cholinergic innervation and the immunoprecipitate of M35 to muscarinic receptors. This pattern is notably clear e.g. in the visual cortex (Parnavelas et al. 1986 ) and parietal somatosensory cortex (Eckenstein et al. 1988; Houser et al. 1985; Lysakowski et al. 1989 ) where a distinct laminar pattern of immunoreactivity to choline acetyltransferase (CHAT) has been demonstrated. ChAT-positive fibers and terminals have a high density in layers 1 and 2, slightly less in layer 3, lowest in layer 4, higher in layer 5 and with medium density in layer 6. In line with the preponderant non-spinous presence of M35 immunoreactivity, the presynaptic immunolabeling with ChAT was localized in endings on dendritic shafts and only rarely on soma membranes or on dendritic spines (Dolabela de Lima and Singer 1986; Houser et al. 1985) . The laminar cortical innervation pattern relates very well with the distribution of M35 immunoreactivity, suggesting a match between presynaptic ChAT and postsynaptic mAChR staining. Moreover, the same pattern of dominance of innervation in layers 1/2 and layer 5 was demonstrated with anterograde tracing from the magnocellular basal nucleus, which is the source of extrinsic cholinergic input from the basal forebrain to the neocortex Spencer et al. 1985) .
The pattern of M35 immunoreactive neurons over the neocortical layers also corresponds to the laminar distribution of cholinoceptive neurons as established by electrophysiological methods ( Autoradiographic detection of radiolabeled ligands to muscarinic receptors in the cortical mantle for a large part agrees well with M35 binding. Most ligand binding studies indicate high concentrations of predominantly M1 type muscarinic receptors in the superficial layers 1-3 of the neocortex (Cort6s et al. 1987; Frey et al. 1985; Kuhar and Yamamura 1976; Mash and Potter 1986; Rotter et al. 1979; Spencer et al. 1986; Vogt 1988 ) and layer 6. Other investigations, however, indicate low muscarinic binding levels in layers 4 and 5, both for specific M1 receptors (Mash and Potter 1986; Spencer et al. 1986 ) and for mAChR in general (Cort6s et al. 1987; Frey et al. 1985; Rotter et al. 1979 ). On the other hand, Spencer et al. (1986) and Mash and Potter (1986) who studied distribution of M2 receptor-specific ligands, report relatively high binding in layer 5, which is supported by findings in the human cortex (Vogt 1988) .
Hippocampus. In the hippocampus, M35 immunoreactivity appears to be well related to cholinergic innervation pathways originating from the medial septum-diagonal band cholinergic cell groups (Geneser 1987; Houser et al. 1983; Nyakas etal. 1987; Storm-Mathisen 1970) . This pattern can be summarized as stratified projections to stratum oriens, pyramidale and the lacunosum-moleculare transition to radiatum of the cornu ammonis (CA). Projections to the fascia dentata (FD) are to the molecular layer, supragranular layer and the polymorphic layer of the hilus (Brady and Vaughn 1988; Frotscher and L&/mth 1985; Geneser 1987; Houser etal. 1983; Nyakas etal. 1987; Storm-Mathisen 1970) . M35 labeling of cell bodies was localized in stratum pyramidale and oriens of the CA and in the granular layer and hilar region of the FD with characteristic labeling of dendrites in stratum radiatum and moleculare. M35 in the molecular layer of the FD had a clear affinity to the apical dendrites of several cell types in and adjacent to the stratum granulosum. However, not all cells of the granular layer reacted immunopositive. In the hippocampus proper, both pyramidal (especially in CA3) and non-pyramidal cells such as multipolar and fusiform interneurons in oriens, radiatum and hilus were found immunoreactive for M35. The putative cholinoceptive character of these categories of neurons corroborates the heterogeneity of hippocampal neurons receiving a cholinergic input (Frotscher and L6rfinth 1986) .
Non-selective muscarinic ligands were found to bind all over the hippocampal formation with highest densities in stratum oriens and radiatum of CA and molecular layer of FD (Cort6s et al. 1987; Frey et al. 1985; Kuhar and Yamamura 1976; Mash and Potter 1986; Rotter et al. 1979; 986). However, labeling with subtype-specific muscarinic antagonists (Mash and Potter 1986; Spencer et al. 1986) indicate that the hippocampus is dominated by M1 receptors, but that localized M2 receptors are present in the pyramidal cell layer and the polymorphic layer of the hilus (Mash and Potter 1986) .
Amygdala. mAChR-immunolabeling with M35 in the amygdaloid body could be characterized by intensely stained cells in the central nucleus and medium dense staining in lateral and basolateral nuclei. This pattern does not fully match the pattern of cholinergic innervation which is dominated by a heavy basal forebrain projection to the basolateral nucleus (Carlsen et al. 1985; K~tsa 1986; Luiten et al. 1987) , whereas the medial part of the central nucleus only displays moderate acetylcholinesterase (AChE)-activity. This apparent discrepancy between M35 cell labeling and presynaptic labeling with cholinergic markers, however, may be partly elucidated by ultrastructural analysis. Immuno-EM study showed dense cytoplasmic staining of central amygdaloid neurons, but very sparse labeling of postsynaptic membrane sites in this amygdaloid nucleus. Conversely, the labeling pattern in the basolateral nucleus was characterized by only moderate to light immunoreactivity in soma and dendrites, but high frequency labeling in dendritic membranes facing presynaptic endings (unpublished observations). Most autoradiographic ligand binding studies indicate the presence of mAChR in several amygdaloid subregions, both of the M1 and the M2 receptor type with relatively highest densities in the lateral cell groups. High levels of M1 labeling have been reported for the medial nucleus (Mash and Potter 1986; Spencer et al. 1986 ).
Basal ganglia. M35 immunoreactivity in the basal ganglia showed a rather differential appearance, not typical of that found in other brain regions. Some cells scattered over the caudate-putamen and clustered in its ventrolateral aspects stained dense with M35. The majority of the cells, however, showed only a light immunopositive reaction. Conversely, in the globus pallidus fewer cells were stained, but more strongly. Ostensibly, this basal ganglia pattern of M35 immunoprecipitate does not match very well with the reportedly high levels of the cholinergic marker enzymes ChAT and AChE (Houser et al. 1983; Kfisa 1986 ) nor with the very high affinity binding of ligands for mAChR and its subtypes M1 and M2 (Cortts et al. 1987; Mash and Potter 1986; Rotter et al. 1979 ; Spencer et al. 1986 ). Preliminary immuno-EM investigation of lightly stained striatal neurons, however, indicate the localized presence of immunoprecipitate in the cytoplasm, dendritic transport system and postsynaptic dendritic membranes. A possible explanation of light staining under LM observation may be that a light immunoreaction corresponds to relatively low concentrations of receptor proteins in the cytoplasm and low levels of protein storage, especially in neurons that are very active in cholinoceptive synaptic processing.
Thalamus. The thalamic nuclei displayed a very rich presence of immunoreactivity after M35 application. Although individual neurons and their dendrites showed mediumdensity staining, the number of labeled cells was very high in various thalamic nuclei. The thalamus as a whole receives a vast and widespread cholinergic input (Hallanger and Wainer 1988; Henderson 1987; Kflsa 1986) . Recent studies combining retrograde intraaxonal transport and ChAT immunocytochemistry clearly indicate massive cholinergic projections to a variety of thalamic nuclei originating from cholinergic sources in both basal forebrain (magnocellular basal nucleus, diagonal band nuclei) and brainstem (pedunculopontine tegmental nucleus and latero-dorsal tegmental nucleus) (Hallanger et al. 1987; Kfisa 1986; Par6 et al. 1988; Woolf and Butcher 1986) .
Binding of ligands to mAChR in the thalamus was reported by several investigators and is very intense in the anteroventral, anterodorsal, anteromedial and lateroposterior nuclei, but considerable in most other thalamic nuclei as well (Cortts et al. 1987; Mash and Potter 1986; Spencer et al. 1986 ). More recent studies employing selective ligands indicate that most of these receptors are of the M2 type (Mash and Potter 1986; Spencer et al. 1986 ).
Muscarinic receptor recognition with immunocytochemistry
From the comparisons made between M35 immunoreactivity, autoradiographic detection of mAChR and cholinergic innervation as described above for several regions of the forebrain, a pattern emerges showing a considerable degree of overlap. Deviations from this basic pattern of cholinergic synaptic organization system may be attributed to a variety of possible causes. A major point of discussion refers to the binding of M35, some of which relate to immunocytochemical detection of receptor proteins in general, and some to muscarinic receptor proteins in particular. Although only a limited number of investigations report on immunocytochemical labeling of receptors (or receptor proteins) they have a few characteristics in common that appear specific for dealing with receptor proteins. First, as in the present study, staining of receptors has been localized in postsynaptic membrane positions (Goldsmith et al. 1979; Lentz and Chester 1977; Nghiem etal. 1983; Sealock etal. 1984; Triller et al. 1985; Van den Pol and Gorcs 1988) in most cases. In our EM-analysis only occasional presynaptic labeling in the cerebral cortex was observed, similarly to the results of Aoki et al. (1987) , who worked with fl-adrenergic receptors. Continued immuno-EM investigation employing more sensitive antibody penetration methods are now in progress to approach this question. Second, several studies on immunocytochemical detection of receptor proteins indicate a relatively sensitive character of receptor proteins. This sensitivity is expressed as susceptibility in staining for fluctuations in immunocytochemical procedures (Deutch et al. 1987 ; this study). Various studies also report heterogeneous sensitivity of antibody binding in different parts of the brain. For example, it was noted by van den Pol and Gorcs (1988) that antibodies to glycine receptors bind strongly in spinal cord and lower brainstem, but only lightly in hippocampus and parts of the olfactory bulb. Antibodies to nicotinic receptor proteins are also reported to show heterogeneous affinity to different cell groups (Deutch et al. 1987) . Differential staining and susceptibility may be due to a large number of causes. One reason may simply be technical: tissue penetration of antibodies and accessibility and recognition of the antigen. In the case of receptor staining, however, we should realize the highly dynamic nature of receptors being subject to complex and multifarious mechanisms of regulation (Liles and Nathanson 1986; Nathanson 1982; Raposo et al. 1987) . Receptor proteins may be present in different concentrations within the cell possibly as a function of their rate of turnover. It is not unlikely that neurons very active in cholinergic synaptic transduction (associated with high AChE activity) may exhibit lower levels of mAChR protein storage than less active cells. In the present study we have seen several examples which may support this assumption e.g. light staining of cells in the caudate-putamen vs. more dense staining in the globus pallidus and heavy precipitate in central amygdala vs. a lighter staining in the basolateral amygdala.
Differential staining with M35 to mAChR, furthermore, may indicate differences in affinity to the various muscarinic receptor subpopulations. There is ample documentation for a pharmacological classification in two (M1, M2) (Hammer et al. 1980) or three (M1-3) (Doods et al. 1987; Waelbroeck et al. 1986; Waelbroeck et al. 1987 ) muscarinic receptor subclasses based on differences in affinity for receptor ligands. More recent molecular studies, employing methods of cloning and protein sequence analysis, however, revealed four distinct but highly homologous gene products designated as HMI-4 for the human receptors (Peralta et al. 1987a and b) and as ml, m3 and m4 (and even m5 ) for rat muscarinic receptors and m2 for a human receptor by Bonner et al. (1987) . Recently, Buckley et al. (1988) reported the distribution of oligonucleotide probes for the above mentioned mlm4 muscarinic receptors in rat brain by in situ hybridization techniques. It may be concluded from that study that their ml, m3 and m4 probes hybridize with structures predominantly in cortex, hippocampus, olfactory regions and basal ganglia collectively corresponding to the distribution of the pharmacological M1 binding sites. Localization of single subtype probes, for example in the basal lateral amygdala and the granular layer of the fascia dentata (ml-subtype), the medial septum and diagonal band (m2-subtype), the lateral septal nucleus, central gray and superior colliculus (m3-subtype) suggests that M35 potentially may recognize most muscarinic subtypes.
It may be clear from the foregoing description of M35 binding and its possible significance for mAChR study that a large number of questions remain to be addressed in greater detail. Currently, our continued interest is focussed on further combined LM and EM analysis of M35 immunoreactive neurons and synaptic membrane-binding distribution in various brain regions. Additional evidence for the binding nature of M35 may come from double-label immunocytochemistry combining M35 postsynaptic labeling and specific cholinergic presynaptic markers such as CHAT, ganglioside chol-1 and anterogradely transported tracers (Borroni et al. 1987; Dolabela de Lima and Singer 1986; Eckenstein et al. 1988; Frotscher and L6rfinth 1985; Luiten et al. 1987 Luiten et al. , 1988 .
